Advisor Group’s Arbutus Biopharma ABUS Stock Holding History

Advisor Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Hold	217	–	–	﹤0.01%	5080
2019 Q3	$0	Hold	217	–	–	﹤0.01%	5245
2019 Q2	$0	Hold	217	–	–	﹤0.01%	5203
2019 Q1	$1K	Hold	217	–	–	﹤0.01%	5018
2018 Q4	$1K	Hold	217	–	–	﹤0.01%	4911
2018 Q3	$2K	Buy	+217	New	+$2.15K	﹤0.01%	4816
2017 Q4	–	Sell	-200	Closed	-$1K	–	4935
2017 Q3	$1K	Sell	200 -400	-67%	-$1.71K	﹤0.01%	4644
2017 Q2	$2K	Hold	600	–	–	﹤0.01%	4487
2017 Q1	$2K	Buy	+600	New	+$1.67K	﹤0.01%	4357

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group's ABUS Position: Q4 2019 in Review

Advisor Group held its Arbutus Biopharma (ABUS) position steady in Q4 2019 at 217 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5080.

Advisor Group first reported a position in ABUS in Q1 2017 and has held it in 9 quarters since. The position peaked at $2K in Q3 2018. 59 funds tracked by Wall St. Rank hold ABUS as of Q4 2019.

Advisor Group held 217 shares of Arbutus Biopharma worth $1K as of Q4 2019.
Advisor Group left its Arbutus Biopharma share count unchanged in Q4 2019.
Arbutus Biopharma made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5080 holding.
Advisor Group first reported a position in Arbutus Biopharma in Q1 2017 and has held it in 9 quarters since.
Advisor Group's Arbutus Biopharma position peaked at $2K in Q3 2018.
59 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.